Renal Denervation in Patients After Acute Coronary Syndrome
Phase 2
- Conditions
- Acute Coronary SyndromeArterial Hypertension
- Interventions
- Registration Number
- NCT01901549
- Lead Sponsor
- Meshalkin Research Institute of Pathology of Circulation
- Brief Summary
This study is aimed to evaluate the effect of renal denervation to decreasing blood pressure and left ventricle remodeling progression in patients after acute coronary syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- acute Q negative myocardium infarction (during first 14 days)
- non stable angina
- significant stenosis
- BP > 140/90 torr. during more than 1 year
Exclusion Criteria
- absence of arterial hypertension
- Thrombolysis during previous 24 hours
- indications for CABG
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PCI+Renal denervation Renal denervation - PCI+Renal denervation Metoprolol - PCI alone Lisinopril - PCI alone Metoprolol - PCI+Renal denervation Lisinopril -
- Primary Outcome Measures
Name Time Method cardiovascular death 1 year myocardium infarction 1 year stroke 1 year repeat revascularization 1 year
- Secondary Outcome Measures
Name Time Method blood pressure changes 1 year CCS and NYHA 1 year heart rhythm disturbances 1 year intima-media index 1 year IVS thickness 1 year restenosis 1 year diastolic disfunction 1 year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie renal denervation's effect on blood pressure and left ventricular remodeling in acute coronary syndrome patients?
How does renal denervation compare to beta-blockers and ACE inhibitors in managing arterial hypertension post-acute coronary syndrome?
Which biomarkers correlate with successful renal denervation outcomes in patients with acute coronary syndrome and hypertension?
What adverse events are associated with renal denervation in acute coronary syndrome patients and how are they managed?
Are there combination therapies involving renal denervation and antihypertensive drugs like metoprolol or lisinopril for post-ACS cardiac remodeling?
Trial Locations
- Locations (1)
State Research Institute of Circulation Pathology
🇷🇺Novosibirsk, Russian Federation
State Research Institute of Circulation Pathology🇷🇺Novosibirsk, Russian FederationEvgeny Pokushalov, MD, PhDPrincipal InvestigatorAlexander Romanov, MDSub InvestigatorAlexander Osiev, MD PhDSub InvestigatorIgor Grazhdankin, MDSub Investigator